Clark Capital Management Group’s Neurocrine Biosciences NBIX Stock Holding History

Clark Capital Management Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.6M	Buy	+92,738	New	+$13.8M	0.09%	170

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clark Capital Management Group's NBIX Position: Q2 2026 in Review

Clark Capital Management Group opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 92,738 shares worth $15.6M. The stake represents 0.09% of the portfolio and ranks #170 among its holdings.

771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Clark Capital Management Group held 92,738 shares of Neurocrine Biosciences worth $15.6M as of Q2 2026.
Neurocrine Biosciences was a new Clark Capital Management Group position in Q2 2026.
Neurocrine Biosciences made up 0.09% of Clark Capital Management Group's portfolio in Q2 2026, its #170 holding.
771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Clark Capital Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.